Access to Medicine Foundation report highlights steps taken by pharmaceutical firms to improve access to medicine


Get RSS feed of these results

All components of this story

22 July 2015

Are pharma giants living up to big promises on development?

Author: Damiano de Felice & Jayasree K Iyer, Access to Medicine Foundation, on Guardian (UK)

The pharmaceutical industry plays a fundamental role in achieving international development targets. This was recognised in the millennium development goals (MDGs), which explicitly mention that providing access to affordable essential drugs in low- and middle-income countries has to be achieved “in cooperation with pharmaceutical companies”…The Access to Medicine Foundation… measures 20 of the world’s largest pharmaceutical companies on their policies and practices for increasing access to medicine. The Foundation’s latest report maps how the pharma companies it tracks are responding to global calls for action on MDG5, which sets targets for reducing deaths during pregnancy and childbirth and for increasing access to contraception and safe abortion…Pharmaceutical companies can also make a significant contribution to MDG5 by addressing the affordability of key products… and by helping to build local capacities…[Refers to GlaxoSmithKline, Merck, Novartis]

Read the full post here

9 April 2015

Improving maternal health and access to contraceptives: Pharmaceutical companies’ contribution to MDG 5

Author: Access to Medicine Foundation

Pharmaceutical companies operationalise commitments to MDG 5 with a variety of initiatives. Ten of the world’s largest pharmaceutical companies are taking some action to improve access to maternal health and family planning, by making public commitments and/or implementing a range of initiatives. This includes five out of six companies with relevant products. All initiatives involve partners and the majority focus on local capacity building. With the Sustainable Development Goals due to be launched this year, this report can be used as a baseline for monitoring whether and how individual research-based pharmaceutical companies are working to improve access to maternal and reproductive health. Measuring progress against such targets is key for maintaining momentum and focus…[Refers to Astellas, Bayer, Daiichi Sankyo, GlaxoSmithKline, Johnson & Johnson, Merck, Novartis, Novo Nordisk (part of Novo Group), Pfizer, Roche, Sanofi]

Read the full post here